Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016

Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016
Published Jun 30, 2016
54 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016, provides in depth analysis on Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50)
- The report reviews Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product po

  
Source:
Document ID
GMDHC0328TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Overview61
Therapeutics Development73
  Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Stage of Development71
  Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Therapy Area81
  Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Indication91
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Products under Development by Companies122
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Therapeutics Assessment147
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action152
  Assessment by Route of Administration172
  Assessment by Molecule Type192
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Companies Involved in Therapeutics Development216
  Abeona Therapeutics, Inc.211
  Alexion Pharmaceuticals, Inc.221
  BioMarin Pharmaceutical Inc.231
  Dorphan S.A.241
  Laboratorios Del Dr. Esteve S.A.251
  UniQure N.V.261
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Drug Profiles2712
  ABO-101 Drug Profile272
  AMT-110 Drug Profile292
  BMN-250 Drug Profile312
  EGT-201 Drug Profile331
  SBC-103 Drug Profile343
  Small Molecule to Target Alpha-N-Acetylglucosaminidase for MPSIIIB Drug Profile371
  Stem Cell Therapy to Activate NAG for Mucopolysaccharidosis III Drug Profile381
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Dormant Projects391
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) Featured News &Press Releases4013
  May 24, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB)401
  Apr 21, 2016: BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)411
  Mar 01, 2016: SBC-103 (rhNAGLU enzyme) Shows a 26.2 Percent Mean Reduction in Heparan Sulfate in Cerebrospinal Fluid at the Highest Dose Studied in Patients with Mucopolysaccharidosis IIIB in Phase 1/2 Study at Six Months421
  Feb 25, 2016: ESTEVE Provides Update On EGT-201 For Sanfilippo B Syndrome431
  Jan 11, 2016: Abeona Therapeutics Announces Initial European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome431
  Sep 19, 2015: Positive Topline Results Announced From Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure's Novel AAV5-Based Gene Therapy441
  Jun 04, 2015: Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB451
  May 20, 2015: PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations For ABX-101 From FDA461
  Jan 26, 2015: Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted461
  Dec 15, 2014: Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB471
  Dec 10, 2014: FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)481
  Feb 12, 2014: Synageva BioPharma Highlights SBC-103 Data at the Lysosomal Disease Network WORLD Symposium482
  Feb 11, 2014: BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B501
  Jan 29, 2014: Synageva BioPharma Announces Data Presentations On SBC-103 at the 10th Annual Lysosomal Disease Network World Symposium511
  Jan 30, 2013: Synageva BioPharma To Present Scientific Data On SBC-103 At 9th Annual LDN WORLD Symposium521
Appendix532
  Methodology531
  Coverage531
  Secondary Research531
  Primary Research531
  Expert Panel Validation531
  Contact Us531
  Disclaimer541

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alpha-N-Acetylglucosaminidase-N-Acetyl-Alpha-Glucosaminidase-or-NAG-or-EC-3-2-1-50-Pipeline-Review-H1-2016-2088-16147>
  
APA:
Global Markets Direct - Market Research. (2016). Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alpha-N-Acetylglucosaminidase-N-Acetyl-Alpha-Glucosaminidase-or-NAG-or-EC-3-2-1-50-Pipeline-Review-H1-2016-2088-16147>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.